The covalent rejoining of DNA ends at single-stranded or double-stranded DNA breaks is catalyzed by DNA ligases. Four DNA ligase activities (I-IV) have been identified in mammalian cells [1] . It has recently been demonstrated that DNA ligase IV interacts with and is catalytically stimulated by the XRCC4 protein [2,3], which is essential for DNA double-strand break repair and the genomic rearrangement process of V(D)J recombination [4] . Together with the finding that the yeast DNA ligase IV homologue is essential for nonhomologous DNA end joining [5] [6] [7] , this has led to the hypothesis that mammalian DNA ligase IV catalyzes ligation steps in both of these processes [8] . DNA ligase IV is characterized by a unique carboxy-terminal tail comprising two BRCT (BRCA1 carboxyl terminus) domains. BRCT domains were initially identified in the breast cancer susceptibility protein BRCA1 [9] , but are also found in other DNA repair proteins [10] . It has been suggested that DNA ligase IV associates with XRCC4 via its tandem BRCT domains and that this may be a general model for protein-protein interactions between DNA repair proteins [3] . We have performed a detailed deletional analysis of DNA ligase IV to define its XRCC4-binding domain and to characterize regions essential for its catalytic activity. We find that a region in the carboxy-terminal tail of DNA ligase IV located between rather than within BRCT domains is necessary and sufficient to confer binding to XRCC4. The catalytic activity of DNA ligase IV is affected by mutations within the first two-thirds of the protein including a 67 amino-acid amino-terminal region that was previously thought not to be present in human DNA ligase IV [11]. 
The basis for the deletional analysis of DNA ligase IV was a PCR clone containing an open reading frame (ORF) from position 274 to 3007 of the published cDNA sequence [11] that was amplified from REH pre-B-cell cDNA. This ORF encodes recombinant DNA ligase IV that is 67 amino acids longer at the amino terminus than the proposed human DNA ligase IV protein [11] . There are two reasons for choosing the longer ORF as a basis for our deletional mutagenesis. First, two independent DNA ligase IV expression vectors containing the shorter ORF expressed inactive DNA ligase IV, whereas several clones encoding the longer ORF yielded DNA ligase IV that was readily active in nick ligation assays (data not shown). Second, alignment of the human and yeast DNA ligase IV protein sequences demonstrated significant homology upstream of the putative start methionine of human DNA ligase IV (Figure 1 ). In fact, the start methionine that was suggested as the first amino acid of human DNA ligase IV is not conserved in yeast (Figure 1 ). Throughout this study we therefore consider the 911 amino-acid version of DNA ligase IV as the wild-type protein.
In order to broadly define functional regions within DNA ligase IV, several deletions covering the entire length of the protein were initially generated as shown in Figure 2a . Deletion mutants L4∆1 and L4∆2 recreated the 'short' version of DNA ligase IV expressed from the putative ATG start codon 475 as suggested by Wei et al. [11] . The mutants differed by their translational initiation sequences (L4∆1 containing the endogenous one and L4∆2 containing a perfect Kozak consensus sequence). Although both Figure 1 Sequence alignment of the amino-terminal 120 amino acids of human DNA ligase IV (hLigIV) and Saccharomyces cerevisiae DNA ligase IV (yLigIV). Identical amino acids are boxed and homologous amino acids are shaded. The location of the putative start methionine of human DNA ligase IV as suggested by Wei et al. [11] is indicated by a black dot. 
L4∆1 and L4∆2 mutants were equally well expressed, they were inactive in nick ligation assays (see Supplementary material). Altogether a total of four independent clones encoding the short form of DNA ligase IV were catalytically inactive. This makes it highly unlikely (p = 0.06 4 = 1.3 × 10 -5 , see Materials and methods) that PCR errors are responsible for this result. We therefore suggest that fully active human DNA ligase IV requires an additional 67 amino-terminal amino acids to the protein originally proposed [11] .
DNA ligase IV deletion mutants L4∆3, L4∆4, L4∆5 and L4∆6 were designed to contain 200 amino-acid deletions throughout the entire protein sequence, whereas mutants L4∆7 and L4∆8 had the carboxy-terminal 111 amino acids deleted (Figure 2a ; L4∆7 and L4∆8 were derived by different cloning strategies). All DNA ligase IV deletion mutants were found to be expressed at comparable levels and could be immunoprecipitated and detected with a monoclonal antibody against their hemagglutinin (HA) epitope tags (Figure 2b ).
Interaction of the various DNA ligase IV mutants with XRCC4 was tested by co-immunoprecipitation with human XRCC4 tagged with the Myc epitope. All DNA ligase IV deletion mutants except mutant L4∆6 were able to efficiently co-immunoprecipitate with XRCC4 ( Figure 2c ). This indicates that a region between amino acids 600 to 800 of DNA ligase IV is essential for XRCC4 binding. Notably, deletion mutants L4∆7 or L4∆8 carrying a deletion of the entire BRCT II domain were not compromised for XRCC4 binding. Analysis of the catalytic activities of mutants L4∆1 to L4∆8 indicated that only the carboxy-terminal 111 amino acids were dispensable (see Supplementary material).
Having identified a 200 amino-acid stretch within the carboxy-terminal tail of DNA ligase IV that is essential for XRCC4 binding, we proceeded to generate further 50-amino-acid deletions within this region ( Figure 3a ). All deletion mutants were found to be expressed (Figure 3b ), and co-immunoprecipitation studies showed that only deletion mutant L4∆12 failed to associate with XRCC4 (Figure 3b,c) . This mutant contains a deletion of the region located between the two BRCT domains. We therefore conclude that this region, rather than the BRCT domains themselves, is required for XRCC4 binding. Whereas wild-type catalytic activity was retained in deletion mutants L4∆10, L4∆11 and L4∆12, we did not detect significant nick ligation activity for deletion mutant L4∆9 (see Supplementary material), for which two independent clones were tested. This deletion is nearest to the proposed catalytic core of DNA ligase IV and it is therefore possible that the deletion either has a structural effect on the catalytic core or that the catalytic domain extends slightly past the first 600 amino acids into the deletion zone of L4∆9.
The finding that the inter-BRCT region of DNA ligase IV is essential for XRCC4 binding does not rule out the possibility that either of the BRCT domains alone might be able to interact with XRCC4 or that the region from amino acids 751 to 800 might be required to bring the BRCT domains into the correct structural context for XRCC4 binding. We therefore created a DNA ligase IV deletion mutant that lacked both BRCT domains (Figure 4a ). Co-immunoprecipitation studies with this mutant demonstrated that even in the complete absence of both BRCT domains DNA ligase IV was able to efficiently bind XRCC4 (Figure 4c ). Therefore the inter-BRCT region of DNA ligase IV is necessary and sufficient for XRCC4 binding. Our study represents the first detailed deletional analysis of a protein, DNA ligase IV, containing BRCT domains, and we find no evidence that these domains are involved in conferring binding to XRCC4. The region in the carboxy-terminal tail of DNA ligase IV that is critical for Brief Communication 875 the interaction with XRCC4 is located in-between rather than within the BRCT domains suggesting a different role of these domains for the function of DNA ligase IV. Tandem BRCT domains were first defined in the carboxy-terminal portion of BRCA1 [9] . BRCA1 binds to the homologous DNA repair factor Rad51, but the interaction occurs via a separate interaction domain located in the center of the protein [12] . The only case where protein-protein binding might be conferred by BRCT domains is in the case of the XRCC1-DNA ligase III association [13] , where the interacting regions have been mapped very closely to the BRCT domains [14] . Because BRCT domains are found in many proteins involved in DNA repair and cell cycle regulation, it will be of considerable interest to determine the main function of BRCT domains, and whether they can influence protein-protein interactions.
Materials and methods

Generation of DNA ligase IV deletion mutants
DNA ligase IV deletion mutants were generated by PCR from expression construct pUG22 containing the DNA ligase IV ORF 274-3007 cloned into pCDNA3 as an HA-tagged version. All PCRs were carried out with KlenTaq DNA polymerase, which has a reduced error rate [15] . Using KlenTaq enzyme the probability per cycle for a point mutation for a 3 kb template is p = 0.03. The probability of a single PCR clone after i PCR cycles is therefore given by:
For many PCR cycles (that is, where i = 40) the probability can be approximated to p = 0.06. Amino-terminal deletions were generated using an internal DNA ligase IV primer and a universal downstream primer binding in the vector backbone. Internal deletion mutants were generated by a two-step PCR approach (see Supplementary material): fusing an amino-terminal piece of the DNA ligase IV cDNA to a carboxy-terminal piece. Deletion mutant L4∆19 carrying a deletion of both BRCT domains was generated by internally deleting the BRCT I domain from deletion mutant L4∆8 that already lacked a BRCT II domain. Individual deletion mutant clones were tested by combinations of 3-4 diagnostic restriction enzyme digests, and in some cases by DNA sequencing.
Transient expression of proteins, immunoprecipitations and western blotting
For all co-immunoprecipitation studies, proteins were transiently expressed in XR-1 CHO cells using the vaccinia virus overexpression system [16] . In cases where constructs were tested for expression, HeLa cells were used instead. Immunoprecipitations of epitope-tagged proteins were performed as described [2] . HA-tagged proteins were occasionally eluted from the immunobeads with 200 mM HA peptide for 16 h at 4°C in order to reduce antibody-derived background signals. Enhanced chemiluminescent western blotting with either purified anti-HA monoclonal antibody 12CA5 or anti-Myc monoclonal antibody 1-9E10.2 was performed as described [17] .
In vitro ligation assays
In vitro ligation assays were performed in 60 mM Tris-Cl, 10 mM MgCl 2 , 5 mM DTT and 5 µg/ml acetylated BSA, pH 7.9. Ligations were performed with 0.1 pmol of a 32 P-labeled nick ligation substrate for 30 min at 37°C, denatured at 95°C in formamide and fractionated by 20% denaturing PAGE. 
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PCR primer sequences for the generation of DNA ligase IV mutants
Universal upstream primer (with BamHI cloning site): 5′-CGGGATC-CATGGCTGCCTCACAAACTTCACAAACTG-3′. Universal downstream primer (with XbaI cloning site): 5′-GCCCTCTAGATGCATGCTC-GAGCGG-3′. Alternative downstream primer for cloning of L4∆8 (with AvrII cloning site): 5′-AAAGCCTAGGCCTCCAAAAAAGCCTCC-3′.
Upstream primers for amino-terminal deletion mutants: L4∆1 (∆aa1-67) 5′-TTATGGATCCATGAGACTAATTCTTCCTCAG-3′. L4∆2 (∆aa1-67, with Kozak sequence): 5′-CTCTGGATCCATG-GCAATGAGACTAATTCTTCCTGAG-3′), L4∆3 (∆aa1-196), 5′-CCATGGATCCATGGTTAGTCAGCAAACTATCTTTTC-3′.
Internal primers for deletion mutants
L4∆4 (∆aa200-400): amino-terminal primer: 5′-GTTTTCTGCACTATTTC-CTGACTAACACCAAGCTTTAAATCCTTTATG-3′, carboxy-terminal primer: 5′-AGCTTGGTGTTAGTCAGGAAATAGTGCAGAAAACA-CAAGCTCATACT-3′. L4∆5 (∆aa381-600): amino-terminal primer: 5′-GCCTTCCCCCTAA-GTTGCTCATGCCCTAGCTTTTTATTATTAACCATC-3′, carboxy-terminal primer: 5′-AAAAGCTAGGGCATGAGCAACTTAGGGGGAAG-GCATCTGGTAAGCTC-3′. Primers for the deletion mutant lacking BRCT domains, L4∆19 (aa∆658-743 plus ∆801-911): amino-terminal primer: 5′-AACGTTAA-CAAAATTTCTAATATTCATATGTGCCCATCAACCAAAGAAC-3′, carboxy-terminal primer: 5′-GGTTGATGGGCACATATGAATATTA-GAAATTTTGTTAACGTTAGTAAG-3′. Table S1 Activity of DNA ligase IV mutants in nick ligation assays.
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Deletion
Catalytic Deletion Catalytic mutant activity* mutant activity Schematic overview of the PCR mutagenesis: a two-step PCR approach for the generation of internal deletion mutants. Two parallel PCRs were performed with full-length DNA ligase IV ORF as a template using universal upstream and downstream cloning primers (primer 1 and primer 2) in combination with internal primers as depicted. The internal primers were designed such that the internal primer for amplification of an amino-terminal fragment of the cDNA had a 18-21 nt 5′ overhang that was complementary to the priming sequence of the internal primer used for amplification of the carboxy-terminal fragment. Likewise, the internal primer for the carboxy-terminal PCR fragment carried a 18-21 nt 5′ overhang that was complementary to the priming sequence of the internal amino-terminal primer. The resulting PCR fragments are therefore identical at their internal ends allowing annealing of DNA strands if the PCR products are combined in a secondary PCR. A fusion product between these PCR fragments is then selectively amplified using the universal upstream and downstream PCR primers. 
